Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Coronavirus Strikes Back. But Force Is Strong With Gold

We all fear the second wave of infections. But the U.S. hasn’t even controlled the first one! Bad news for Americans, but good news for gold. Please take a look at the chart below. As you can see, the epidemiological situation in the United States d...
Arkadiusz Sieron | June 30, 2020 |

Will CoronaVirus Pandemic Trigger a Stocks Bear Market 2020? Part1

The stock market is confounding growing Coronavirus fears by recovering all of the late January's drop in the wake of Coronavirus news out of China that started global alarm bells ringing of what could transpire right across the world. The Dow retraced all of its drop from 2...
Nadeem Walayat | February 12, 2020 |

Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial

Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results ...
Streetwise Reports | December 30, 2019 |

Will the Second Wave Trigger Rally in Gold?

The initial health crisis seems to be under control in many countries. But this is not the end of pandemic and many epidemiologist warn against the second wave of injections. We invite you to read our today’s article about the second wave of the new coronavirus...
Arkadiusz Sieron | June 19, 2020 |

XPhyto to Announce PCR Test Kit Final Validation Results

It could be the Holy Grail of COVID-19 testing. Remarkably, a small Canadian life sciences company, XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) is becoming a front-runner in the race to bring this breakthrough technology to market – starting with Germany. This ref...
Marc Davis | November 26, 2020 |

T2 Biosystems Shares Nearly Double on Worldwide COVID-19 Testing License Deal

Shares of T2 Biosystems Inc. traded 90% higher after the company reported that a new COVID-19 assay licensed from Hackensack Meridian Health's Center for Discovery and Innovation will be adapted to run on its FDA-cleared T2Dx® Instrument. Diagnostic...
Streetwise Reports | March 26, 2020 |

Steady Gold Amid Choppy Recovery

Initial jobless claims are declining painfully slowly. The disconnect between the choppy recovery and financial markets creates upward risk for gold. The initial jobless claims still paint grim picture . They amounted to 1.48 million in the week from June 13 to June 2...
Arkadiusz Sieron | July 2, 2020 |

Surging Retail Sales, Cautious Powell, and Gold

Retail sales came in really strong in May, which could strengthen risk appetite, but the dovish Fed should support gold. However, the sales were still 6 percent lower than a year ago, which means that the coronavirus crisis has not ended yet. But such reports may, neve...
Arkadiusz Sieron | June 18, 2020 |

Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax

Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. Late yesterday afternoon, biopharmaceutical company Paratek Pharmaceuti...
Streetwise Reports | December 20, 2019 |

Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data

Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. Clinical-stage biotechnology company Moderna Inc. (MRNA:NASDAQ) , which fo...
Streetwise Reports | May 19, 2020 |
1 2 3 4 5 6 7 8 9